$0.37
(Market cap
$2,476 Mln
Revenue (TTM)
$55 Mln
P/E Ratio
--
P/B Ratio
2.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
-6.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7.3
-
Face value
--
-
Shares outstanding
34,142,994
10 Years Aggregate
CFO
$-1,245.55 Mln
EBITDA
$-932.67 Mln
Net Profit
$-1,757.19 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
| 69.7 | 1.5 | 10.6 | 140.3 | 100.3 | -20.9 | -12.3 |
|
BSE Sensex*
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
| 203.1 | 65.4 | -75.2 | -83.3 | -20.5 | -21.2 | -34.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
|
71.8 | 2,476.1 | 54.6 | -157.1 | -169.8 | -31.6 | -- | 2.8 |
| 17.7 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 202.8 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 23.9 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.3 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 66.9 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 132.1 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Nektar Therapeutics (NKTR)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune... system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California. Read more
-
CEO, President & Director
Mr. Howard W. Robin
-
CEO, President & Director
Mr. Howard W. Robin
-
Headquarters
San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Nektar Therapeutics (NKTR)
What is the current share price of Nektar Therapeutics (NKTR) Today?
The share price of Nektar Therapeutics (NKTR) is $71.75 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Nektar Therapeutics (NKTR) has given a return of 100.33% in the last 3 years.
What is the current PB & PE ratio of Nektar Therapeutics (NKTR)?
Since, TTM earnings of Nektar Therapeutics (NKTR) is negative, P/E ratio is not available.
The P/B ratio of Nektar Therapeutics (NKTR) is 2.82 times as on 28-Aug-2026, a 64 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-5.23 |
9.55 |
2024 |
-0.11 |
0.22 |
2023 |
-0.03 |
0.05 |
2022 |
-0.08 |
0.08 |
2021 |
-0.32 |
0.25 |
What is the 52 Week High and Low of Nektar Therapeutics (NKTR)?
The 52-week high and low of Nektar Therapeutics (NKTR) are Rs 109.00 and Rs 27.87 as of 02-Sep-2026.
What is the market cap of Nektar Therapeutics (NKTR)?
Nektar Therapeutics (NKTR) has a market capitalisation of $ 2,476 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Nektar Therapeutics (NKTR)?
Before investing in Nektar Therapeutics (NKTR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.